Role of the Functional Toll-Like Receptor-9 Promoter Polymorphism (-1237T/C) in Increased Risk of End-Stage Renal Disease: A Case-Control Study

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Yang, Hsin Yi ^a   Lu, Kuo Cheng ^b   Lee, Herng Sheng ^c   Huang, Shih Ming ^a   Lin, Yuh Feng ^c,d   Wu, Chia Chao ^c   Salter, Donald M ^e   Su, Sui Lung ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; INTERLEUKIN 6; LUCIFERASE; MESSENGER RNA; TOLL LIKE RECEPTOR 9; TLR9 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEMODIALYSIS; HIGH RISK POPULATION; HUMAN; HUMAN CELL; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMOTER REGION; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; TRANSCRIPTION REGULATION; ALLELE; BLOOD; CHRONIC KIDNEY FAILURE; CYTOLOGY; DISEASE COURSE; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENETICS; HEK293 CELL LINE; INFLAMMATION; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION;

AGED; ALLELES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEK293 CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; TOLL-LIKE RECEPTOR 9; TRANSCRIPTION, GENETIC;

EID: 84874613091     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058444     Document Type: Article

References (48)

1. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, et al. (2008) All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 371: 2173-2182.
2. Satko SG, Sedor JR, Iyengar SK, Freedman BI, (2007) Familial clustering of chronic kidney disease. Semin Dial 20: 229-236.
3. Adler S, (2006) Renal disease: environment, race, or genes? Ethn Dis 16: S2-35-39.
4. Eleftheriadis T, Lawson BR, (2009) Toll-like receptors and kidney diseases. Inflamm Allergy Drug Targets 8: 191-201.
5. Smith KD, (2009) Toll-like receptors in kidney disease. Curr Opin Nephrol Hypertens 18: 189-196.
6. Koc M, Toprak A, Arikan H, Odabasi Z, Elbir Y, et al. (2011) Toll-like receptor expression in monocytes in patients with chronic kidney disease and haemodialysis: relation with inflammation. Nephrol Dial Transplant 26: 955-963.
7. Schwartz DA, Cook DN, (2005) Polymorphisms of the Toll-like receptors and human disease. Clin Infect Dis 41 (Suppl 7):: S403-407.
8. Dalpke A, Zimmermann S, Heeg K, (2002) CpG DNA in the prevention and treatment of infections. Bio Drugs 16: 419-431.
9. Summers SA, Steinmetz OM, Ooi JD, Gan PY, O'Sullivan KM, et al. (2010) Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis. Am J Pathol 177: 2234-2244.
10. Summers SA, Hoi A, Steinmetz OM, O'Sullivan KM, Ooi JD, et al. (2010) TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. J Autoimmun 35: 291-298.
11. Bochud PY, Hersberger M, Taffe P, Bochud M, Stein CM, et al. (2007) Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 21: 441-446.
12. Krayenbuehl PA, Hersberger M, Truninger K, Mullhaupt B, Maly FE, et al. (2010) Toll-like receptor 4 gene polymorphism modulates phenotypic expression in patients with hereditary hemochromatosis. Eur J Gastroenterol Hepatol 22: 835-841.
13. Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, et al. (2008) Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 19: 2384-2395.
14. Kubarenko AV, Ranjan S, Rautanen A, Mills TC, Wong S, et al. (2010) A naturally occurring variant in human TLR9, P99L, is associated with loss of CpG oligonucleotide responsiveness. J Biol Chem 285: 36486-36494.
15. Lange NE, Zhou X, Lasky-Su J, Himes BE, Lazarus R, et al. (2011) Comprehensive genetic assessment of a functional TLR9 promoter polymorphism: no replicable association with asthma or asthma-related phenotypes. BMC Med Genet 12: 26.
16. Carvalho A, Osorio NS, Saraiva M, Cunha C, Almeida AJ, et al. (2011) The C allele of rs5743836 polymorphism in the human TLR9 promoter links IL-6 and TLR9 up-regulation and confers increased B-cell proliferation. PLoS One 6: e28256.
17. Lu KC, Yang HY, Lin YF, Kao SY, Lai CH, et al. (2011) The T-1237C polymorphism of the Toll-like receptor-9 gene is associated with chronic kidney disease in a Han Chinese population. Tohoku J Exp Med 225: 109-116.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470.
19. Hamann L, Hamprecht A, Gomma A, Schumann RR, (2004) Rapid and inexpensive real-time PCR for genotyping functional polymorphisms within the Toll-like receptor-2,-4, and-9 genes. J Immunol Methods 285: 281-291.
20. Soriano-Sarabia N, Vallejo A, Ramirez-Lorca R, Rodriguez Mdel M, Salinas A, et al. (2008) Influence of the Toll-like receptor 9 1635A/G polymorphism on the CD4 count, HIV viral load, and clinical progression. J Acquir Immune Defic Syndr 49: 128-135.
21. Barrett JC, Fry B, Maller J, Daly MJ, (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
22. Kopple JD, Greene T, Chumlea WC, Hollinger D, Maroni BJ, et al. (2000) Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int 57: 1688-1703.
23. Gama-Axelsson T, Heimburger O, Stenvinkel P, Barany P, Lindholm B, et al. (2012) Serum albumin as predictor of nutritional status in patients with ESRD. Clin J Am Soc Nephrol 7: 1446-1453.
24. Jansen MA, Korevaar JC, Dekker FW, Jager KJ, Boeschoten EW, et al. (2001) Renal function and nutritional status at the start of chronic dialysis treatment. J Am Soc Nephrol 12: 157-163.
25. Faresjo T, Faresjo A, (2010) To match or not to match in epidemiological studies-same outcome but less power. Int J Environ Res Public Health 7: 325-332.
26. Ng MW, Lau CS, Chan TM, Wong WH, Lau YL, (2005) Polymorphisms of the toll-like receptor 9 (TLR9) gene with systemic lupus erythematosus in Chinese. Rheumatology (Oxford) 44: 1456-1457.
27. Wu JF, Chen CH, Ni YH, Lin YT, Chen HL, et al. (2012) Toll-like receptor and hepatitis B virus clearance in chronic infected patients: a long-term prospective cohort study in Taiwan. J Infect Dis 206: 662-668.
28. Velez DR, Wejse C, Stryjewski ME, Abbate E, Hulme WF, et al. (2010) Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, and West Africans. Hum Genet 127: 65-73.
29. Lazarus R, Klimecki WT, Raby BA, Vercelli D, Palmer LJ, et al. (2003) Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics 81: 85-91.
30. Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, et al. (2004) Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 18: 534-536.
31. Anders HJ, Banas B, Schlondorff D, (2004) Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15: 854-867.
32. Török HP, Glas J, Endres I, Tonenchi L, Teshome MY, et al. (2009) Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. Am J Gastroenterol 104: 1723-1733.
33. Soriano-Sarabia N, Vallejo A, Ramírez-Lorca R, Rodríguez MM, Salinas A, et al. (2008) Influence of the Toll-like receptor 9 1635A/G polymorphism on the CD4 count, HIV viral load, and clinical progression. J Acquir Immune Defic Syndr 49: 128-135.
34. Kikuchi K, Lian ZX, Kimura Y, Selmi C, Yang GX, et al. (2005) Genetic polymorphisms of toll-like receptor 9 influence the immune response to CpG and contribute to hyper-IgM in primary biliary cirrhosis. J Autoimmun 24: 347-352.
35. Xu CJ, Zhang WH, Pan HF, Li XP, Xu JH, et al. (2009) Association study of a single nucleotide polymorphism in the exon 2 region of toll-like receptor 9 (TLR9) gene with susceptibility to systemic lupus erythematosus among Chinese. Mol Biol Rep 36: 2245-2248.
36. Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, et al. (2008) Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 19: 2384-2395.
37. Sato D, Suzuki Y, Kano T, Suzuki H, Matsuoka J, et al. (2012) Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrol Dial Transplant 27: 1090-1097.
38. Holla LI, Vokurka J, Hrdlickova B, Augustin P, Fassmann A, (2009) Association of Toll-like receptor 9 haplotypes with chronic periodontitis in Czech population. J Clin Periodontol 37: 152-159.
39. De Jager PL, Richardson A, Vyse TJ, Rioux JD, (2006) Genetic variation in toll-like receptor 9 and susceptibility to systemic lupus erythematosus. Arthritis Rheum 54: 1279-1282.
40. Takeshita F, Suzuki K, Sasaki S, Ishii N, Klinman DM, et al. (2004) Transcriptional regulation of the human TLR9 gene. J Immunol 173: 2552-2561.
41. Ng MT, Van't Hof R, Crockett JC, Hope ME, Berry S, et al. (2010) Increase in NF-kappaB binding affinity of the variant C allele of the toll-like receptor 9-1237T/C polymorphism is associated with Helicobacter pylori-induced gastric disease. Infect Immun 78: 1345-1352.
42. Novak N, Yu CF, Bussmann C, Maintz L, Peng WM, et al. (2007) Putative association of a TLR9 promoter polymorphism with atopic eczema. Allergy 62: 766-772.
43. Hasuike Y, Nonoguchi H, Ito K, Naka M, Kitamura R, et al. (2009) Interleukin-6 is a predictor of mortality in stable hemodialysis patients. Am J Nephrol 30: 389-398.
44. Zoccali C, Tripepi G, Mallamaci F, (2006) Dissecting inflammation in ESRD: Do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 17: S169-S173.
45. Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, et al. (2010) Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 25: 205-212.
46. Smith AJ, Humphries SE, (2009) Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 20: 43-59.
47. Ljungman P, Bellander T, Nyberg F, Lampa E, Jacquemin B, et al. (2009) DNA variants, plasma levels and variability of interleukin-6 in myocardial infarction survivors: results from the AIRGENE study. Thromb Res 124: 57-64.
48. Giachelia M, Voso MT, Tisi MC, Martini M, Bozzoli V, et al. (2012) Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kappaB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 53: 411-416.